Perspective Therapeutics’ (CATX) Outperform Rating Reaffirmed at Wedbush

Wedbush reaffirmed their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a research report released on Monday morning,RTT News reports. Wedbush currently has a $11.00 price objective on the stock.

Several other analysts have also recently commented on the company. Scotiabank began coverage on Perspective Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 target price for the company. Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 4th. Oppenheimer decreased their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. Brookline Capital Management raised Perspective Therapeutics to a “strong-buy” rating in a research report on Monday, March 10th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating, eight have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $14.56.

Perspective Therapeutics Price Performance

CATX opened at $2.60 on Monday. The business has a fifty day simple moving average of $3.12 and a 200-day simple moving average of $7.11. Perspective Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.05.

Institutional Trading of Perspective Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Y Intercept Hong Kong Ltd bought a new position in Perspective Therapeutics during the fourth quarter valued at about $33,000. Intech Investment Management LLC bought a new position in Perspective Therapeutics during the third quarter valued at about $137,000. Aigen Investment Management LP bought a new position in Perspective Therapeutics during the fourth quarter valued at about $34,000. National Bank of Canada FI raised its holdings in Perspective Therapeutics by 549,900.0% during the fourth quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after buying an additional 10,998 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Perspective Therapeutics during the third quarter valued at about $152,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.